News
Article
Author(s):
This review of the latest dermatologic studies includes insights into disparities in pediatric atopic dermatitis, nurse-led models for skin cancer detection, and more.
A recent scoping review explored disparities in pediatric atopic dermatitis (AD) in the United States. Researchers systematically analyzed 53 studies published between January 2021 and May 2024, focusing on inequities related to race/ethnicity, socioeconomic status, region, sex/gender, and language. Most studies examined racial and ethnic disparities, followed by socioeconomic, regional/environmental, sex/gender, and language factors. The review highlighted disparities in AD prevalence, health outcomes, and access to care.1
A recent systematic review evaluated nurse-led models for skin cancer detection, analyzing their roles, clinical effectiveness, and added benefits. Out of 6680 records screened, six studies involving 3325 patients from England, New Zealand, and the US met inclusion criteria. Findings showed that nurse-led care offered high diagnostic accuracy, reduced waiting times, and improved patient access and satisfaction. Although direct comparisons with dermatologist-led care were limited, 1 study found nurses performed comparably to ophthalmologists in diagnosis. The review suggests nurse-led models can effectively support or supplement physician care in skin cancer management.2
A recent multicenter study assessed the dermatophyte spectrum and infection types in German university hospitals in 2018 and 2023. The study analyzed mycological cultures from 1915 patients, with findings showing a shift in dermatophyte prevalence. Trichophyton rubrum remained the most common dermatophyte, but infections caused by Trichophyton tonsurans significantly increased, particularly in tinea capitis, which doubled from 4.3% to 9.3%. In 2023, Trichophyton tonsurans became the leading pathogen in tinea capitis (67.6%) and the second most common in tinea corporis (26.3%). The median age of affected patients with Trichophyton tonsurans was 18 years, a marked increase from 9 years in 2018, with a higher proportion of male patients.3
A recent study introduced the Kesty Hyperpigmentation Scale (KHS), a new clinical tool designed to evaluate facial hyperpigmentation consistently in both cosmetic and medical dermatology settings. The scale, developed through a rigorous validation process, demonstrated strong reliability and validity based on various statistical analyses, including Gwet's AC2 and Kendall’s W. The KHS uses a 0–3 rating scale and provides an objective way to measure hyperpigmentation severity, making it easier for clinicians to monitor patient progress after treatment. The tool was well-received by participants, who found it user-friendly and expressed interest in using it to enhance patient communication and document treatment outcomes.4
A literature review examined the differences between oral and subcutaneous methotrexate (MTX) for treating chronic plaque-type psoriasis, focusing on absorption, bioavailability, efficacy, safety, patient satisfaction, adherence, and costs. Thirty-two articles, including clinical trials and guidelines, were reviewed, with European guidelines favoring subcutaneous MTX. The review found that subcutaneous MTX may address some limitations of the oral form, such as absorption and bioavailability, and potentially offers higher efficacy and better adherence. Further research is needed, particularly as biologic treatments become more common.5
References
What new studies have you been involved with or authored? Share with us by emailing DTEditor@mmhgroup.com for an opportunity to be featured.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.